By Dr. Shweta Agarwal, MBBS, DGO Medically reviewed by Dr. Shweta Agarwal, MBBS, DGO Last updated: June 2026
Information on this page is educational and does not replace a medical consultation. Outcomes depend on individual clinical factors.
Aansh Hospital & IVF Center is a government-registered Level-2 ART clinic (Reg. No. MH/AC/2024/15441/L2/Chandrapur/132), part of a growing chain of fertility centres across Vidarbha and northern Telangana, with our headquarters and in-house embryology lab in Chandrapur. You can verify our government ART registration directly on the National ART & Surrogacy Registry.
One of the questions I am asked most often in consultations — by patients across our Vidarbha and Telangana centres — is some version of: "Does my age actually make that much difference?" The Marathi shorthand वय आणि आयव्हीएफ यश ("age and IVF success") captures exactly what most people want to understand before they begin.
The honest answer is: yes, age matters enormously in IVF — and the reason is biological, not arbitrary. But understanding why age matters leads to a more nuanced picture than a single headline number ever can. It also opens the door to a genuinely useful conversation about what you can and cannot change, and what your individual assessment should include.
This post explains the biology, walks through what published international-registry data tells us qualitatively about age-banded outcomes, and frames what an individualised assessment actually looks like. For a deeper dive into how to interrogate any specific success-rate figure — denominators, definitions, sample size — the companion post How to Read an IVF Success-Rate Claim is a natural next step.
Why is female age the dominant factor in IVF outcomes?
Female age is the dominant variable in IVF outcomes because of what happens to egg biology as a woman ages — specifically to the quality of the eggs that are retrieved and fertilised.
Every woman is born with her entire lifetime supply of eggs. From puberty onward, this supply diminishes with each menstrual cycle. But the quantity of eggs — ovarian reserve — is only part of the picture. The other part, which is clinically more consequential for IVF success, is egg quality.
Egg quality refers primarily to the chromosomal integrity of the egg. A chromosomally normal egg, when fertilised by a normal sperm, produces an embryo with the correct number and structure of chromosomes — a euploid embryo. A chromosomally abnormal egg produces an aneuploid embryo, which either fails to implant, results in a very early pregnancy loss, or in some cases continues to a detectable miscarriage.
The critical biological fact is this: the proportion of chromosomally abnormal eggs increases substantially with maternal age. In younger women, the majority of eggs are chromosomally normal. From the mid-thirties onward, the proportion of aneuploid eggs rises progressively — and the rate of increase steepens into the late thirties and forties. This is not a cliff edge at a single age; it is a gradient that becomes more pronounced with time.
Because IVF outcomes are ultimately determined by how many viable, chromosomally competent embryos are available for transfer, and because egg aneuploidy rate is the primary driver of embryo viability, female age — acting through egg quality — is the single largest variable in the equation.
How does egg quantity (ovarian reserve) differ from egg quality?
These two concepts are frequently conflated, and the distinction matters enormously for how you interpret your own test results.
Ovarian reserve refers to the number of eggs remaining in the ovaries — the quantity of the remaining egg supply. The two most commonly used markers of ovarian reserve are anti-Müllerian hormone (AMH) and antral follicle count (AFC), measured on ultrasound. AMH is a hormone produced by small follicles; its blood level correlates with the number of follicles available to respond to stimulation. AFC is a direct ultrasound count of small antral follicles at the start of a cycle.
Both AMH and AFC tell us about how many eggs we are likely to be able to retrieve in an IVF cycle. A higher AMH and AFC predict a stronger response to stimulation and, typically, more eggs retrieved. A lower AMH or AFC predicts fewer eggs — which means fewer embryos to work with overall.
Egg quality, by contrast, is the chromosomal and developmental competence of individual eggs. Critically, AMH does not measure egg quality. A woman can have an AMH in the low-normal range and have excellent egg quality; conversely, a woman with a high AMH can still produce a proportion of aneuploid eggs that rises with age.
The practical consequence: two women of the same age with similar AMH levels can have different IVF outcomes. Two women with very different AMH levels but the same age will tend to face similar egg-quality challenges. Ovarian reserve determines how many eggs you start with; age is the dominant determinant of what proportion of those eggs are likely to be chromosomally competent.
This is why an individualised assessment combining age, AMH, and AFC together — rather than any single marker in isolation — gives the most useful picture. You can request a fertility assessment at Aansh that covers both markers.
How do live-birth rates shift across age bands in IVF?
The honest way to discuss IVF success by age is qualitatively, with any specific figures attributed to published international-registry data and clearly marked as needing verification against the most current source.
Published data from large international fertility registries consistently shows the following pattern for live-birth rates per transfer using a woman's own eggs:
- Under 35: Live-birth rates per transfer are at their highest. The majority of embryos from this age group are chromosomally normal, and implantation rates are correspondingly stronger.
- 35–37: Rates begin to decline. The decline at this stage is measurable but often modest. Many women in this group have outcomes that are still in a broadly comparable range to the under-35 band, though individual variation is substantial.
- 38–39: The decline becomes more pronounced. Aneuploidy rates are rising more steeply, and the number of chromosomally normal embryos available from each retrieval decreases for most women. More retrievals may be needed to accumulate enough viable embryos.
- 40–42: A significant further decline in live-birth rates per transfer. The proportion of aneuploid eggs is considerably higher, and more cycles are often required to achieve a successful transfer. Miscarriage rates within pregnancies that do occur are also higher, because a proportion of the aneuploid embryos that implant are lost in early pregnancy.
- 43–44 and above: Live-birth rates using own eggs are substantially lower still. International registry data shows a steep reduction in this band. Success remains possible but becomes less probable per cycle, and cumulative rates may still be meaningful with multiple cycles.
These are population-level patterns. Individual outcomes within each band vary considerably depending on ovarian reserve, specific diagnosis, male-partner factors, embryo quality, and uterine factors. The pattern above should be read as a framework for understanding the direction and relative magnitude of the age effect — not as a prediction for any specific patient.
For the methodology behind how to read any single quoted figure — denominator, definition of success, fresh vs frozen — refer to How to Read an IVF Success-Rate Claim.
What is egg aneuploidy and why does it drive both lower implantation and higher miscarriage?
Aneuploidy means an abnormal number of chromosomes in a cell. In the context of IVF, egg aneuploidy refers to eggs that have the wrong number of chromosomes — most often an extra or missing chromosome rather than the normal complement of 23 pairs.
When an aneuploid egg is fertilised, the resulting embryo is also aneuploid. The vast majority of aneuploid embryos either fail to implant at all (the transfer occurs but no pregnancy is detected) or result in a very early pregnancy loss — sometimes before the patient is even aware a pregnancy had begun. A small proportion implant and are detected as a biochemical or clinical pregnancy but then miscarry. A very small proportion of specific aneuploidies (notably trisomy 21, 18, and 13) can progress further, and some can result in ongoing pregnancies.
The clinical effect of rising aneuploidy with age is therefore felt in two ways: lower implantation rates per transfer (fewer embryos successfully implant to begin with), and higher miscarriage rates among the pregnancies that do establish (because a proportion of what implanted was chromosomally abnormal). This is why the age-related decline in IVF outcomes is not just about getting pregnant — it is also about staying pregnant.
Pre-implantation genetic testing for aneuploidy (PGT-A) is a laboratory technique that allows embryos to be screened for chromosomal abnormalities before transfer. It identifies which embryos in a cohort are euploid. PGT-A can reduce the transfer of embryos likely to fail — which may improve the success rate per transfer of screened embryos — but it does not increase the number of euploid embryos produced; it only selects among what is available. The benefit of PGT-A is subject to ongoing clinical debate, particularly for younger patients, and is discussed individually during consultation.
Does male age affect IVF outcomes too?
Male age does contribute to IVF outcomes, though its effect is less pronounced and operates differently from female age.
Sperm, unlike eggs, are produced continuously throughout a man's life rather than from a fixed lifetime supply. The primary concern with advancing male age is a gradual increase in sperm DNA fragmentation and a rise in de novo genetic mutations in sperm — changes that can affect embryo quality and developmental potential. There is also evidence of a modest increase in miscarriage risk associated with older paternal age, and some data suggesting a small decline in fertilisation rates in older men.
However, the magnitude of the male-age effect is considerably smaller than the female-age effect in most clinical scenarios. In practice, when we see declining IVF outcomes in a couple as female age increases, the egg-quality factor is the dominant driver — not the sperm. Male-factor issues are assessed with a semen analysis, and if DNA fragmentation is a concern, specific testing can be added.
The distinction is clinically important because donor sperm and donor eggs address different parts of the equation, and understanding which factor is contributing more to the outcome picture shapes the treatment path.
What is the role of donor eggs, and when does it change the prognosis?
Donor egg IVF is an option in situations where a woman's own egg quality or ovarian reserve has reduced to the point where own-egg IVF is unlikely to result in a live birth, or where repeated own-egg cycles have not succeeded despite good laboratory results.
The key biological fact that makes donor eggs clinically meaningful is this: in IVF, it is primarily the age of the egg donor — not the age of the recipient's uterus — that determines the chromosomal quality of the embryos. The uterus retains a relatively strong capacity to support a pregnancy well into the mid-forties in most women, provided the endometrium responds adequately to hormonal preparation. Published international-registry data shows that live-birth rates in donor-egg cycles are substantially higher than own-egg rates for older recipients, and that recipient age has a much smaller effect on outcomes when donor eggs are used.
This is not a recommendation, and it is not a pathway that is right for everyone. Many patients in their late thirties and early forties achieve pregnancies with their own eggs, and an individualised assessment is always the starting point. Donor eggs represent an option when own-egg prognosis is significantly reduced — not a default, and not a shortcut.
At Aansh, donor egg IVF is offered only through our registered ART Bank (Reg. No. MH/AB/2024/11445/Chandrapur/91). All donors are recruited, screened, and matched in compliance with the Assisted Reproductive Technology (Regulation) Act 2021. Any discussion of donor options is educational and individualised to your clinical picture.
What can and cannot be changed — and what actually helps?
Understanding what is in and outside of your control is, in my experience, one of the most useful things a consultation can provide.
What cannot be changed: Your chronological age and the egg quality that comes with it cannot be reversed. There is no supplement, protocol, or intervention that regenerates the chromosomal integrity of eggs that have aged. Claims to the contrary — particularly from supplements marketed at "egg quality improvement" — should be viewed with significant scepticism unless supported by well-designed clinical trial data.
What can be changed or optimised:
- Not delaying further: If you are in your mid-to-late thirties and considering IVF, earlier investigation is more useful than waiting. This is not a pressure statement — it is a reflection of the biological trend above. A fertility assessment now gives you more information and more options than the same assessment later.
- Protocol optimisation: Stimulation protocol, trigger timing, embryo culture conditions, and transfer approach can be adjusted based on your specific ovarian response and history. These decisions are made by the clinical team in response to your actual cycle, not a generic template.
- Lifestyle factors: Smoking is consistently associated with poorer ovarian reserve and egg quality; stopping smoking is the most evidence-supported lifestyle modification. Excessive alcohol, very high or very low BMI, and chronic sleep deprivation may all have modest effects. Antioxidant supplementation is sometimes used; evidence is mixed and should be discussed individually.
- Fertility preservation: If you are not yet ready for pregnancy but are in your late twenties or thirties, egg freezing (oocyte cryopreservation) allows eggs retrieved now — at their current age-associated quality — to be stored for later use. This is an option worth exploring independently of any immediate treatment plan. For more detail, see the planned guide Egg Freezing: Who Should Consider It and When.
The most useful starting point is an individualised assessment — AMH blood test plus ultrasound AFC — which gives a concrete picture of your current ovarian reserve and allows your clinician to give you age-appropriate, evidence-based information about your specific situation rather than population averages.
How should I interpret my AMH result in the context of age?
AMH (anti-Müllerian hormone) is the most commonly measured marker of ovarian reserve, and it is useful — but it requires careful interpretation alongside your age.
AMH naturally declines with age. What counts as "normal" or "adequate" for a woman at 28 is different from what is expected at 38. A result that sits in the low-normal range for a woman in her early thirties may be more concerning for a woman in her mid-twenties (because it suggests faster-than-expected reserve decline), while the same absolute number may be reassuring for a woman in her early forties (because it suggests relatively preserved reserve for her age).
This is why AMH results should always be interpreted by a clinician with your age, AFC, and clinical history in front of them — not by comparing your number against a generic internet reference range.
The other limitation of AMH, which is worth repeating: AMH measures egg quantity (reserve), not egg quality. A low AMH tells us the ovarian response to stimulation may be reduced — meaning fewer eggs retrieved per cycle — but it does not tell us how many of those eggs are chromosomally normal. That is primarily determined by age. Conversely, a high AMH does not guarantee good egg quality; in PCOS, for example, AMH is typically elevated due to a large number of small follicles, but egg quality in PCOS is not necessarily superior.
If you have an AMH result you want to discuss in the context of your full picture, a fertility assessment at Aansh or a free second opinion with Dr. Shweta Agarwal are both good starting points.